Please login to the form below
Data by
5
Revenue 2014Merck & Co.
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck & Co.'s 2013 sales performance.
GSK makes case for revaccination with Shingrix
The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... Zostavax meanwhile has seen revenues slide from around $750m
GSK makes case for revaccination with Shingrix
The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... Zostavax meanwhile has seen revenues slide from around $750m
Smart solutions
It is not just GSK that is under pressure. The likes of AstraZeneca’s Symbicort (budesonide and formoterol), Merck &Co’s Dulera (formoterol and mometasone) and Teva’s Qvar (beclometasone) are ... Dana Shears is eMDI business development director of
EP downgrades long-term sales projections for pharma
It expects Merck &Co's Keytruda (pembrolizumab) to topple Bristol-Myers Squibb's Opdivo (nivolumab) as the top-selling drug in that class by that year.
FDA panel backs CV claims for Novo Nordisk's Victoza
Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| US revenue 2014 |
|---|
| 1: Gilead Sciences |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Roche |
| 5: Novartis |
| 6: Amgen |
| 7: Merck & Co. |
| 8: Sanofi |
| 9: AbbVie |
| 10: Actavis |
| 11: AstraZeneca |
| 12: GlaxoSmithKline |
| 13: Lilly |
| 14: Bristol-Myers Squibb |
| 15: Novo Nordisk |
| Oncology revenue 2014 |
|---|
| 1: Roche |
| 2: Novartis |
| 3: Celgene |
| 4: Johnson & Johnson |
| 5: Bristol-Myers Squibb |
| 6: Lilly |
| 7: Takeda |
| 8: AstraZeneca |
| 9: Merck & Co. |
| 10: Amgen |
| 11: Pfizer |
| 12: Astellas |
| 13: Bayer |
| 14: Otsuka |
| 15: Sanofi |
| 16: Merck KGaA |
| 17: Eisai |
| 18: AbbVie |
| 19: Pharmacyclics |
| 20: Incyte |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| Cardiovascular revenue 2014 |
|---|
| 1: AstraZeneca |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Daiichi Sankyo |
| 5: Pfizer |
| 6: Novartis |
| 7: Bayer |
| 8: Takeda |
| 9: Boehringer Ingelheim |
| 10: Astellas |
| 11: Actelion |
| 12: Johnson & Johnson |
| 13: Shionogi |
| 14: United Therapeutics |
| 15: Bristol-Myers Squibb |
| 16: Gilead Sciences |
| 17: Otsuka |
| 18: Roche |
| 19: Lilly |
| 20: The Medicines Company |
| Metabolic revenue 2014 |
|---|
| 1: Novo Nordisk |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Lilly |
| 5: AstraZeneca |
| 6: Takeda |
| 7: Novartis |
| 8: Amgen |
| 9: Bayer |
| 10: Merck KGaA |
| 11: Salix Pharmaceuticals |
| 12: AbbVie |
| 13: Dainippon Sumitomo Pharma |
| 14: Kyowa Hakko Kirin |
| 15: Mitsubishi Tanabe |
| Biologic revenue 2014 |
|---|
| 1: Roche |
| 2: Amgen |
| 3: Novo Nordisk |
| 4: AbbVie |
| 5: Sanofi |
| 6: Johnson & Johnson |
| 7: Pfizer |
| 8: Merck & Co. |
| 9: Lilly |
| 10: Biogen Idec |
| 11: Merck KGaA |
| 12: GlaxoSmithKline |
| 13: Bristol-Myers Squibb |
| 14: Novartis |
| 15: Bayer |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
- Senior Director, Healthcare PR, Home Counties
-
Competitive
- Account Director - Healthcare Advertising - London
-
£50000 - £68000
-
Scientific Director
-
£70, 000 - £85, 000
- Senior Corporate Communications Manager
-
Competitive Salary
-
Brand Communications Manager
-
A competitive salary plus bonus
-
Head of Marketing Insulin
-
Competitive Salary
- Account Director or Senior Account Director, Healthcare Advertis...
-
£55, 000 - £65, 000 benefits
- 6-12 MONTH FREELANCE OPPORTUNITY - ACCOUNT DIRECTOR or SENIOR AC...
-
SUPERB DAY RATE AVAILABLE
-
Senior Medical Writer
-
Great salary and benefits
-
Principal Medical Writer
-
Great salary and benefits
- Senior Account Manager – Healthcare PR
-
Salary TBC
- FREELANCE *Client Service/ Project Manager*
-
Competitive Salary
-
*Multi-Channel Creative Designer*
-
Competitive Salary
- Account Manager, Healthcare PR, Global and UK
-
£33, 000 – £40, 000
-
*Design Manager*
-
Competitive Salary
-
Director – Healthcare PR/ Policy
-
Salary TBC
-
Account Director - Med Comms
-
Great salary and benefits
- Account Manager, Medical Communications
-
£30, 000-£40, 000
Subscribe to our email news alerts
- Sanofi continues pharma's trend of ditching the corporate blog
- Bayer wins FDA approval for MS electronic autoinjector and app
- Warning sounded on pharma's long-term sales prospects
- Facing the new wave of biosimilars
- Sandoz joins Europe's MabThera biosimilar push
- FDA panel backs CV claims for Novo Nordisk's Victoza
- The new pharma marketing playbook
- PEGASUS SHOWREEL 2017
- Alzheon says data backs potential of Alzheimer's candidate
- Shift to value-based medicine will boost mHealth uptake
- Ashfield to host global webinar on Patient Service Team on 10 July
- Pharma needs to evolve from customer-centricity to stakeholder-centricity
PMHub
Brandcast Health
Brandcast Health is a digital MedComms and patient-engagement agency who help our clients create and share engaging content. Our innovative...
Latest intelligence
- The new pharma marketing playbook
- Learn about the 5 areas that must be in your pharma marketing playbook...
- Pharma needs to evolve from customer-centricity to stakeholder-centricity
- Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....
- 5 health behavioural factors to incorporate in your marketing
- Achieve real health behaviour change by including these elements in your pharmaceutical marketing....
Quick links
Infographics
